Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease

• Published in: Journal of medicinal chemistry Vol. 65; no. 20; pp. 13852 - 13865
• Main Authors: Hirose, Yuya, Shindo, Naoya, Mori, Makiko, Onitsuka, Satsuki, Isogai, Hikaru, Hamada, Rui, Hiramoto, Tadanari, Ochi, Jinta, Takahashi, Daisuke, Ueda, Tadashi, Caaveiro, Jose M. M., Yoshida, Yuya, Ohdo, Shigehiro, Matsunaga, Naoya, Toba, Shinsuke, Sasaki, Michihito, Orba, Yasuko, Sawa, Hirofumi, Sato, Akihiko, Kawanishi, Eiji, Ojida, Akio
• Format: Journal Article
• Language: English
• Published: WASHINGTON American Chemical Society 27.10.2022; Amer Chemical Soc
• Subjects: Chemistry, Medicinal; Life Sciences & Biomedicine; Pharmacology & Pharmacy; Science & Technology; ROUTE; ACID

The coronavirus disease 2019 (COVID-19) pandemic has necessitated the development of antiviral agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 3C-like protease (3CLpro) is a promising target for COVID-19 treatment. Here, we report a new class of covalent inhibitors of 3C...